The Epilepsy Bioinformatics Study for Antiepileptogenic Therapy (EpiBioS4Rx)

抗癫痫治疗的癫痫生物信息学研究（EpiBioS 4 Rx）是响应RFA-NS-16-012的CWOW提案，旨在通过消除障碍和促进基础和临床神经科学家的多学科团队的大规模合作研究工作，促进抗癫痫治疗的开发，这些团队可以访问广泛的患者人群，明确定义和严格标准化的动物模型，和尖端的分析方法我们将我们的建议集中在创伤性脑损伤（TBI）后创伤后癫痫（PTE）的抗癫痫发生上，因为这种情况提供了确定患者癫痫发生过程发作时间的最佳机会。EpiBioS 4 Rx科学预测是：TBI后的癫痫发生可以通过特定的治疗来预防;相关生物标志物的鉴定和严格的临床前试验的性能将允许未来设计和执行经济可行的抗癫痫治疗的全面临床试验。基于P20规划补助金的工作，我们的计划将包括以下内容：（1）在我们的动物模型和患者中鉴定癫痫发生的生物标志物，（2）开发和利用用于潜在抗癫痫（AEG）药物的临床前试验的标准化平台，（3）鉴定1种或多种用于未来干预性临床试验的先导抗癫痫药物，（4）建立先进的TBI中心网络，能够进行未来的临床试验，其中包括我们的主要抗癫痫药物，这些药物在个性化的背景下使用，利用我们的生物标志物小组以药物为基础的方法，以及（5）开发并纳入涉及消费者相互教育和合作的公众参与计划，消费者组织和专业人士设计和执行未来的抗癫痫治疗的大规模干预性临床试验。

The Epilepsy Bioinformatics Study for Antiepileptogenic Therapy (EpiBioS4Rx), a CWOW proposal in response to RFA-NS-16-012, is designed to facilitate the development of antiepileptogenic therapies by removing barriers and promoting large-scale collaborative research efforts by multidisciplinary teams of basic and clinical neuroscientists with access to extensive patient populations, well-defined and rigidly standardized animal models, and cutting-edge analytic methodology. We focus our proposal on antiepileptogenesis in post- traumatic epilepsy (PTE) following traumatic brain injury (TBI), as this condition offers the best opportunity to determine the time of onset of the epileptogenic process in patients. The EpiBioS4Rx Scientific Premise is: Epileptogenesis after TBI can be prevented with specific treatments; the identification of relevant biomarkers and performance of rigorous preclinical trials will permit the future design and performance of economically feasible full-scale clinical trials of antiepileptogenic therapies. Based on the work from a P20 planning grant, our program will consist of the following: (1) identify biomarkers of epileptogenesis in our animal model and in patients, (2) Develop and utilize a standardized platform for preclinical trials of potential antiepileptogenic (AEG) drugs, (3) Identify 1 or more lead antiepileptogenic drugs for a future interventional clinical trial, (4) Establish a network of advanced TBI centers capable of carrying out future clinical trials featuring our lead antiepileptogenic drugs used in the context of a personalized, medicine-based approach utilizing our panel of biomarkers, and (5) Develop and incorporate a public engagement program involving the mutual education and collaboration of consumers, consumer organizations and professionals to design and execute future large-scale interventional clinical trials of antiepileptogenic therapies.